Consumption of antimicrobials in animals reaches lowest level ever in Europe

European Surveillance of Veterinary Antimicrobial Consumption (ESVAC): 2009 - 2023

Human medicines European public assessment report (EPAR): Tagrisso, osimertinib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 01/02/2016, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 21/09/2018, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Darzalex, daratumumab, Multiple Myeloma, Date of authorisation: 20/05/2016, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Fingolimod Mylan, fingolimod, Multiple Sclerosis, Relapsing-Remitting, Date of authorisation: 18/08/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Revatio, sildenafil, Hypertension, Pulmonary, Date of authorisation: 28/10/2005, Revision: 50, Status: Authorised

Human medicines European public assessment report (EPAR): Ajovy, fremanezumab, Migraine Disorders, Date of authorisation: 28/03/2019, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Jaypirca, pirtobrutinib, Lymphoma, Mantle-Cell, Date of authorisation: 30/10/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Suboxone, buprenorphine,naloxone, Opioid-Related Disorders, Date of authorisation: 26/09/2006, Revision: 22, Status: Authorised